Opinion | TrumpRx deal with Eli Lilly and Novo Nordisk creates a bad precedent

In a landmark deal announced Thursday, President Donald Trump negotiated dramatically lower costs for weight-loss drugs produced by pharmaceutical giants Eli Lilly and Novo Nordisk, which could benefit Medicare and Medicaid patients, as well as Americans paying out of pocket. But here’s the skinny: What the president negotiated should not be reserved for big companies that play his game.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source